Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

Takaaki Nakashima; Takeshi Nonoshita; Hidenari Hirata; Kouji Inoue; Akira Nagashima; Tadamasa Yoshitake; Kaori Asai; Yoshiyuki Shioyama

doi:10.21873/invivo.11767

Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

Takaaki Nakashima, Takeshi Nonoshita, Hidenari Hirata, Kouji Inoue, Akira Nagashima, Tadamasa Yoshitake, Kaori Asai, Yoshiyuki Shioyama

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

Original language	English
Pages (from-to)	247-253
Number of pages	7
Journal	In Vivo
Volume	34
Issue number	1
DOIs	https://doi.org/10.21873/invivo.11767
Publication status	Published - 2020

All Science Journal Classification (ASJC) codes

Biochemistry, Genetics and Molecular Biology(all)
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/invivo.11767

Cite this

@article{3e80840cb66f4ccdb90e329c786f66a8,

title = "Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma",

abstract = "Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.",

author = "Takaaki Nakashima and Takeshi Nonoshita and Hidenari Hirata and Kouji Inoue and Akira Nagashima and Tadamasa Yoshitake and Kaori Asai and Yoshiyuki Shioyama",

note = "Funding Information: This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grant numbers: 18K07718). Publisher Copyright: {\textcopyright} 2020 International Institute of Anticancer Research. All rights reserved.",

year = "2020",

doi = "10.21873/invivo.11767",

language = "English",

volume = "34",

pages = "247--253",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

AU - Nakashima, Takaaki

AU - Nonoshita, Takeshi

AU - Hirata, Hidenari

AU - Inoue, Kouji

AU - Nagashima, Akira

AU - Yoshitake, Tadamasa

AU - Asai, Kaori

AU - Shioyama, Yoshiyuki

N1 - Funding Information: This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grant numbers: 18K07718). Publisher Copyright: © 2020 International Institute of Anticancer Research. All rights reserved.

PY - 2020

Y1 - 2020

N2 - Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

AB - Background: We investigated acute adverse events in patients with brain metastases (BMs) of anaplastic lymphoma kinase-rearranged (ALKr) non-small cell lung cancer (NSCLC) treated with both cranial radiotherapy and tyrosine kinase inhibitors (TKIs) of ALK. Patients and Methods: Acute AEs were retrospectively investigated in patients with BMs of ALKr-NSCLC who received both whole-brain radiotherapy (WBRT) and ALK-TKI. For comparison, they were also assessed in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and wild-type with neither ALK rearrangement nor EGFR mutation treated with WBRT. Results: Two ALKr cases were consequently eligible. Grade 3 otitis media unexpectedly occurred in both cases, while there was one case out of 11 and one case out of 18 of grade 2 otitis media among the EGFR-mutated cases and wild-type cases (p=0.013), respectively. Conclusion: Concurrent treatment with WBRT and ALK-TKI may be associated with acute severe ear toxicity in patients with BMs of ALKr-NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=85077252304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077252304&partnerID=8YFLogxK

U2 - 10.21873/invivo.11767

DO - 10.21873/invivo.11767

M3 - Article

C2 - 31882485

AN - SCOPUS:85077252304

SN - 0258-851X

VL - 34

SP - 247

EP - 253

JO - In Vivo

JF - In Vivo

IS - 1

ER -

Adverse events of concurrent radiotherapy and ALK inhibitors for brain metastases of ALK-rearranged lung adenocarcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this